ライフサイエンスコーパス: hepatic blood flow

1 ation leading to a marked reduction in fetal hepatic blood flow.

2 hildren by inhibiting lipolysis and reducing hepatic blood flow.

3 duced by temporal and segmental occlusion of hepatic blood flow.

4 techniques were used to quantify changes in hepatic blood flow.

5 acaval shunt (HGPCS) on portal and effective hepatic blood flow.

6 possibly a result of excessive diminution of hepatic blood flow.

7 preservation, and enhanced energy charge and hepatic blood flow after reperfusion.

8 galactose (V(max)/K(m)) from measurements of hepatic blood flow and arterial and liver vein blood gal

9 er Transplantation Cohort Study was to study hepatic blood flow and effect of portal flow modulation

10 ration of a nitric oxide (NO) donor restored hepatic blood flow and increased the expression of the m

11 rtant in the regulation of liver metabolism, hepatic blood flow, and bile secretion.

12 ased availability of nitric oxide, decreased hepatic blood flow, and increased inflammatory cytokines

13 Intestinal and hepatic blood flow (assessed by laser Doppler flowmetry)

14 asive longitudinal hemodynamic monitoring of hepatic blood flow before and after TIPS placement.

15 asive longitudinal hemodynamic monitoring of hepatic blood flow before and after transjugular intrahe

16 Epinephrine caused increased hepatic blood flow centrally (171.1% +/- 31.7) but not p

17 Effective hepatic blood flow decreased during the HS period from a

18 h decreased liver injury, enhanced effective hepatic blood flow, decreased cytokines, and prevention

19 ively to undergo TIPS or HGPCS had effective hepatic blood flow determined 1 day preshunt and 5 days

20 Effective hepatic blood flow (EHBF) by galactose clearance, wet-dr

21 ratio (E(IE), the ratio of IE clearance over hepatic blood flow) > 0.05.

22 The hepatic blood flow of male Sprague Dawley rats was subje

23 Effective hepatic blood flow remained constant in the sham groups

24 rved after I/R may be due to improvements in hepatic blood flow secondary to altered hepatic hemodyna

25 Total hepatic blood flow (THBF) and HM was measured along with

26 been proposed that this therapy may improve hepatic blood flow via the vasodilating properties of PG

27 of (11)C-CSar from hepatocytes to blood, and hepatic blood flow was 25% higher than in experiments wi

28 Hepatic blood flow was determined by indocyanine green i

29 Effective hepatic blood flow was diminished significantly after TI

30 eased slowly and peaked 20 to 30 hours after hepatic blood flow was restored.

31 s in blood led to clearance values above the hepatic blood flow, whereas the (S)-enantiomers were una